Evidence map›Paper›PMID 24423492›Full record

ArticleMolecular oncology2014

LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF-B signaling.

Aleksandar Kuzmanov, Ulrike Hopfer, Patricia Marti, Nathalie Meyer-Schaller, Mahmut Yilmaz, Gerhard Christofori

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Role of microRNA-129 in cancer and non-cancerous diseases (Review).Experimental and therapeutic medicine · 2021
    Review
  17. Effect ofTranslational cancer research · 2021
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aleksandar KuzmanovDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
Ulrike HopferDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland; Novartis, Basel, Switzerland.
Patricia MartiDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland; Novartis, Basel, Switzerland.
Nathalie Meyer-SchallerDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
Mahmut YilmazDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland; Roche, Basel, Switzerland.
Gerhard ChristoforiDepartment of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland. Electronic address: gerhard.christofori@unibas.ch.
University of Basel · CHNovartis (Switzerland) · CHRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An epithelial-mesenchymal transition (EMT) is a critical process during embryonic development and the progression of epithelial tumors to metastatic cancers. Gene expression profiling has uncovered the transcription factor LIM homeobox gene 2 (Lhx2) with up-regulated expression during TGFβ-induced EMT in normal and cancerous breast epithelial cells. Loss and gain of function experiments in transgenic mouse models of breast cancer and of insulinoma in vivo and in breast cancer cells in vitro indicate that Lhx2 plays a critical role in primary tumor growth and metastasis. Notably, the transgenic expression of Lhx2 during breast carcinogenesis promotes vessel maturation, primary tumor growth, tumor cell intravasation and metastasis by directly inducing the expression of platelet-derived growth factor (PDGF)-B in tumor cells and by indirectly increasing the expression of PDGF receptor-β (PDGFRβ) on tumor cells and pericytes. Pharmacological inhibition of PDGF-B/PDGFRβ signaling reduces vessel functionality and tumor growth and Lhx2-induced cell migration and cell invasion. The data indicate a dual role of Lhx2 during EMT and tumor progression: by inducing the expression of PDGF-B, Lhx2 provokes an autocrine PDGF-B/PDGFRβ loop required for cell migration, invasion and metastatic dissemination and paracrine PDGF-B/PDGFRβ signaling to support blood vessel functionality and, thus, primary tumor growth.

Indexed as

Autocrine CommunicationParacrine CommunicationSignal TransductionAnimalsBreast NeoplasmsCell MovementEpithelial-Mesenchymal TransitionFemaleHumansLIM-Homeodomain ProteinsMammary Neoplasms, ExperimentalMiceNeoplasm InvasivenessNeoplasm MetastasisProto-Oncogene Proteins c-sisReceptor, Platelet-Derived Growth Factor betaLhx1 protein, mouseLHX2 protein, humanLIM-Homeodomain ProteinsProto-Oncogene Proteins c-sisReceptor, Platelet-Derived Growth Factor betaTranscription FactorsEMTLhx2MetastasisPDGF-BTumor progression

Identifiers

PMID24423492
PMCPMC5528541
OpenAlexW2032663621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.